Camzyos and Anesthesia
Continue Camzyos (mavacamten) on the day of surgery with extreme caution, but strongly consider holding it perioperatively in patients with obstructive hypertrophic cardiomyopathy (HCM) undergoing noncardiac surgery, as factors that aggravate dynamic left ventricular outflow tract (LVOT) obstruction—including anesthesia-induced hemodynamic changes—are harmful and must be avoided.
Critical Clarification: Camzyos vs. Tafamidis
Important: The question appears to conflate two different medications. Camzyos (mavacamten) is FDA-approved for obstructive HCM, while tafamidis (Vyndaqel/Vyndamax) is approved for transthyretin amyloid cardiomyopathy (ATTR-CM). These are distinct diseases requiring different perioperative approaches. The expanded question mentions ATTR-CM but asks about Camzyos—I will address both scenarios.
For Camzyos (Mavacamten) in Obstructive HCM Patients
Perioperative Management Algorithm
Pre-operative Assessment:
- LVEF must be ≥50% before proceeding with elective surgery 1
- If LVEF <50%, interrupt Camzyos immediately and postpone elective surgery 1
- Obtain echocardiogram within 4 weeks of planned surgery to assess LVEF and Valsalva LVOT gradient
Day of Surgery Decision:
- Consider holding Camzyos 3-5 days before surgery given:
Anesthetic Precautions for HCM Patients (On or Off Camzyos)
The 2026 AHA/ACC perioperative guideline provides explicit recommendations for HCM 2:
Avoid these factors that worsen LVOT obstruction:
- Positive inotropic agents (dobutamine, epinephrine, dopamine)
- Tachycardia (maintain heart rate control)
- Reduced preload (hypovolemia, excessive diuresis)
- Reduced afterload (hypotension)
Recommended intraoperative management:
- Continue beta-blockers and/or non-dihydropyridine calcium channel blockers throughout the perioperative period 2
- Maintain adequate preload with intravenous fluids
- If hypotension develops:
- Prioritize IV fluid administration first
- Use alpha-agonists (phenylephrine or vasopressin) rather than beta-agonists 2
- Consider intravenous beta-blockade to reduce contractility and relieve LVOT obstruction
- Consider intraoperative transesophageal echocardiography (TEE) to evaluate LVOT obstruction if hemodynamic instability occurs 2
- Maintain sinus rhythm due to LV hypertrophy and decreased compliance 2
Post-operative Monitoring
- Obtain echocardiogram before restarting Camzyos to confirm LVEF ≥50% 1
- Monitor for heart failure symptoms or worsening clinical status 1
- If intercurrent illness (infection, arrhythmia) occurs, delay Camzyos restart 1
For Tafamidis in ATTR-CM Patients
Perioperative Management
Continue tafamidis through the perioperative period as:
- It is a transthyretin stabilizer that prevents amyloid fibril formation 3
- Well-tolerated with safety profile similar to placebo 4, 5, 6
- Reduces all-cause mortality and cardiovascular hospitalizations 3, 4
- No specific perioperative contraindications exist in guidelines
- Abrupt discontinuation may accelerate disease progression
Anesthetic Considerations for ATTR-CM
ATTR-CM patients have restrictive cardiomyopathy with:
- Reduced ventricular compliance
- Diastolic dysfunction
- Conduction abnormalities
- Autonomic dysfunction
Key perioperative principles:
- Maintain preload (these patients are preload-dependent)
- Avoid excessive fluid administration (risk of pulmonary edema)
- Maintain sinus rhythm (atrial contribution to ventricular filling is critical)
- Avoid tachycardia (impairs diastolic filling)
- Monitor for arrhythmias (high risk of atrial fibrillation, conduction disease)
- Consider invasive hemodynamic monitoring for major surgery
Common Pitfalls to Avoid
- Confusing Camzyos with tafamidis—completely different drugs for different diseases
- Using inotropes in HCM patients—worsens LVOT obstruction 2
- Allowing hypovolemia in HCM—exacerbates obstruction 2
- Stopping tafamidis unnecessarily—no evidence supports perioperative discontinuation
- Failing to check LVEF before surgery in Camzyos patients—mandatory per FDA label 1
- Ignoring drug interactions—Camzyos has significant CYP2C19/CYP3A4 interactions 1
Summary Algorithm
If patient has obstructive HCM on Camzyos:
- Check LVEF <4 weeks before surgery
- If LVEF ≥50%: Consider holding Camzyos 3-5 days pre-op
- Continue beta-blockers/calcium channel blockers
- Avoid inotropes, maintain preload, use alpha-agonists for hypotension
- Check LVEF before restarting Camzyos post-op
If patient has ATTR-CM on tafamidis:
- Continue tafamidis perioperatively
- Manage restrictive physiology: maintain preload, avoid fluid overload
- Monitor for arrhythmias
- Maintain sinus rhythm and avoid tachycardia